Claims for Patent: 7,520,866

Summary for Patent: 7,520,866

Title:	Device and method for treatment of wounds with nitric oxide
Abstract:	Topical exposure of nitric oxide gas to wounds such as chronic non-healing wounds may be beneficial in promoting healing of the wound and in preparing the wound bed for further treatment and recovery. Nitric oxide gas may be used, for example, to reduce the microbial infection and burden on these wounds, manage exudate secretion by reducing inflammation, upregulate expression of endogenous collagenase to locally debride the wound, and regulate the formation of collagen. High concentration of nitric oxide ranging from about 160 to 400 ppm may be used without inducing toxicity in the healthy cells around a wound site. Additionally, exposure to the high concentration for a first treatment period reduces the microbial burden and inflammation at the wound site and increase collagenase expression to debride necrotic tissue at the wound site. After a first treatment period with high concentration of nitric oxide, a second treatment period at a lower concentration of nitric oxide preferably ranging from about 5-20 ppm may to provided to restore the balance of nitric oxide and induce collagen expression to aid in the closure of the wound.
Inventor(s):	Stenzler; Alex (Long Beach, CA), Miller; Chris C (North Vancouver, CA)
Assignee:	Sensormedics Corporation (Yorba Linda, CA) Pulmonox Technologies Corporation (Edmonton, Alberta, CA)
Application Number:	11/487,600
Patent Claims:	1. A method for wound bed preparation, the method comprising the steps of: diagnosing a wound site of a subject, providing a flow-controlled source of nitric oxide containing gas, debriding necrotic tissue located at the wound site by exposing the wound site, for a treatment period, to a high concentration of exogenous nitric oxide gas from the flow-controlled source of nitric oxide containing gas; and exposing the wound to a low concentration of exogenous nitric oxide gas for a second treatment period sufficient to induce the expression of new collagen. 2. The method of claim 1, further comprising grafting skin onto the wound site. 3. The method of claim 1, wherein during the debriding step, the endogenous expression of collagenase is induced in situ at the wound site. 4. The method of claim 1, wherein the wound site is exposed to the high concentration of exogenous nitric oxide gas for a period of at least 7 hours. 5. The method of claim 1, wherein the wound site is exposed to the high concentration of exogenous nitric oxide gas for a period of at least 48 hours. 6. The method of claim 1, wherein the high concentration of exogenous nitric oxide gas is about 200 ppm. 7. The method of claim 1, wherein the high concentration of exogenous nitric oxide gas is from about 120 ppm to about 400 ppm. 8. The method of claim 1, wherein the low concentration of exogenous nitric oxide gas is from about 5 ppm to about 20 ppm. 9. The method of claim 1, wherein the wound site is exposed to the low concentration of exogenous nitric oxide gas for a period of at least 7 hours.

Details for Patent 7,520,866

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2020-12-26